Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(24):1863-1877; doi:10.1093/jnci/94.24.1863
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Spänkuch-Schmitt, B.
Right arrow Articles by Strebhardt, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spänkuch-Schmitt, B.
Right arrow Articles by Strebhardt, K.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 24, 1863-1877, December 18, 2002
© 2002 Oxford University Press


ARTICLE

Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells

Birgit Spänkuch-Schmitt, Jürgen Bereiter-Hahn, Manfred Kaufmann, Klaus Strebhardt

Affiliation of authors: B. Spänkuch-Schmitt, M. Kaufmann, K. Strebhardt (Department of Obstetrics and Gynecology, School of Medicine), J. Bereiter-Hahn (Department of Biology), J. W. Goethe-University, Frankfurt, Germany.

Correspondence to: Prof. Dr. K. Strebhardt, Department of Obstetrics and Gynecology, J. W. Goethe-University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany (e-mail: Strebhardt{at}em.uni-frankfurt.de).

Background: Expression of polo-like kinase-1 (PLK1), which has several functions in mitotic progression, is elevated in a broad range of human tumors. To investigate the role of PLK1 in neoplastic proliferation, we used the technique of RNA interference. Methods: Cells from several different cancer cell lines (MCF-7 breast cancer cells, HeLa S3 cervical cancer cells, SW-480 colon cancer cells, and A549 lung cancer cells) were transfected with small interfering (si) RNAs targeted against the human PLK1 or lamin genes. Northern and western blot analyses were used to examine PLK1 gene expression in transfected cancer cells and normal cells (human mammary epithelial cells [HMECs]). The phenotype, proliferation, and cell cycle distribution of cells transfected with siRNAs were also monitored by fluorescence microscopy and fluorescence-activated cell sorting analysis. Results: All cancer cell lines transfected with low doses of siRNAs targeted to PLK1 had greatly decreased levels of PLK1 mRNA and protein. siRNA4, which had the strongest inhibitory effect, reduced PLK1 mRNA in MCF-7 cells by 70% and PLK1 protein in MCF-7 cells by 95% 24 hours after transfection. Cell proliferation was reduced by between 66% and 99% 48 hours after transfection, and apoptosis was increased from 1%–5% to 13%–50% in transfected cells. Transfected SW-480 cells were mitotically arrested, and their centrosomes had lost the ability to nucleate microtubules. HMECs took up siRNAs less efficiently than cancer cells, and transfection with siRNAs targeted to PLK1 did not inhibit their proliferation. Conclusions: PLK1 function appears to be essential for centrosome-mediated microtubule events and, consequently, for spindle assembly. siRNAs targeted against human PLK1 may be valuable tools as antiproliferative agents that display activity against a broad spectrum of neoplastic cells at very low doses.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
A. G. Gilmartin, M. R. Bleam, M. C. Richter, S. G. Erskine, R. G. Kruger, L. Madden, D. F. Hassler, G. K. Smith, R. R. Gontarek, M. P. Courtney, et al.
Distinct Concentration-Dependent Effects of the Polo-like Kinase 1-Specific Inhibitor GSK461364A, Including Differential Effect on Apoptosis
Cancer Res., September 1, 2009; 69(17): 6969 - 6977.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Adler, K. Muller, E. Rached, W. Dekant, and A. Mally
Modulation of key regulators of mitosis linked to chromosomal instability is an early event in ochratoxin A carcinogenicity
Carcinogenesis, April 1, 2009; 30(4): 711 - 719.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. J. McManus, I. J. Barrett, Y. Nouhi, and P. Hieter
Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing
PNAS, March 3, 2009; 106(9): 3276 - 3281.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. C. Nappi, P. Salerno, H. Zitzelsberger, F. Carlomagno, G. Salvatore, and M. Santoro
Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma
Cancer Res., March 1, 2009; 69(5): 1916 - 1923.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
Y. Ren, W. Gong, H. Zhou, Y. Wang, F. Xiao, and T. Li
siRecords: a database of mammalian RNAi experiments and efficacies
Nucleic Acids Res., January 1, 2009; 37(suppl_1): D146 - D149.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. Mross, A. Frost, S. Steinbild, S. Hedbom, J. Rentschler, R. Kaiser, N. Rouyrre, D. Trommeshauser, C. E. Hoesl, and G. Munzert
Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors
J. Clin. Oncol., December 1, 2008; 26(34): 5511 - 5517.
[Abstract] [Full Text] [PDF]


Home page
BioinformaticsHome page
W. Gong, Y. Ren, H. Zhou, Y. Wang, S. Kang, and T. Li
siDRM: an effective and generally applicable online siRNA design tool
Bioinformatics, October 15, 2008; 24(20): 2405 - 2406.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
E. Kawata, E. Ashihara, S. Kimura, K. Takenaka, K. Sato, R. Tanaka, A. Yokota, Y. Kamitsuji, M. Takeuchi, J. Kuroda, et al.
Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer
Mol. Cancer Ther., September 1, 2008; 7(9): 2904 - 2912.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
T. L Schmit and N. Ahmad
Regulation of Mitosis via Mitotic Kinases: New Opportunities for Cancer Management
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 133 - 150.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Koida, T. Ozaki, H. Yamamoto, S. Ono, T. Koda, K. Ando, R. Okoshi, T. Kamijo, K. Omura, and A. Nakagawara
Inhibitory Role of Plk1 in the Regulation of p73-dependent Apoptosis through Physical Interaction and Phosphorylation
J. Biol. Chem., March 28, 2008; 283(13): 8555 - 8563.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. L. Schmit and N. Ahmad
Regulation of mitosis via mitotic kinases: new opportunities for cancer management
Mol. Cancer Ther., July 1, 2007; 6(7): 1920 - 1931.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. E. Morgan-Lappe, L. A. Tucker, X. Huang, Q. Zhang, A. V. Sarthy, D. Zakula, L. Vernetti, M. Schurdak, J. Wang, and S. W. Fesik
Identification of Ras-Related Nuclear Protein, Targeting Protein for Xenopus Kinesin-like Protein 2, and Stearoyl-CoA Desaturase 1 as Promising Cancer Targets from an RNAi-Based Screen
Cancer Res., May 1, 2007; 67(9): 4390 - 4398.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
T. J. Lansing, R. T. McConnell, D. R. Duckett, G. M. Spehar, V. B. Knick, D. F. Hassler, N. Noro, M. Furuta, K. A. Emmitte, T. M. Gilmer, et al.
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
Mol. Cancer Ther., February 1, 2007; 6(2): 450 - 459.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
S. Kappel, Y. Matthess, B. Zimmer, M. Kaufmann, and K. Strebhardt
Tumor inhibition by genomically integrated inducible RNAi-cassettes
Nucleic Acids Res., September 11, 2006; 34(16): 4527 - 4536.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. L. Garland, C. Taylor, D. L. Pilkington, J. L. Cohen, and D. D. Von Hoff
A Phase I Pharmacokinetic Study of HMN-214, a Novel Oral Stilbene Derivative with Polo-Like Kinase-1-Interacting Properties, in Patients with Advanced Solid Tumors
Clin. Cancer Res., September 1, 2006; 12(17): 5182 - 5189.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B. Spankuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, J. Yuan, M. Kaufmann, and K. Strebhardt
Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo
Cancer Res., June 1, 2006; 66(11): 5836 - 5846.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
X. Liu, M. Lei, and R. L. Erikson
Normal cells, but not cancer cells, survive severe plk1 depletion.
Mol. Cell. Biol., March 1, 2006; 26(6): 2093 - 2108.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Eckerdt, J. Yuan, K. Saxena, B. Martin, S. Kappel, C. Lindenau, A. Kramer, S. Naumann, S. Daum, G. Fischer, et al.
Polo-like Kinase 1-mediated Phosphorylation Stabilizes Pin1 by Inhibiting Its Ubiquitination in Human Cells
J. Biol. Chem., November 4, 2005; 280(44): 36575 - 36583.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
X. Liu, C.-Y. Lin, M. Lei, S. Yan, T. Zhou, and R. L. Erikson
CCT Chaperonin Complex Is Required for the Biogenesis of Functional Plk1
Mol. Cell. Biol., June 15, 2005; 25(12): 4993 - 5010.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Guan, P. Tapang, J. D. Leverson, D. Albert, V. L. Giranda, and Y. Luo
Small Interfering RNA-Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals
Cancer Res., April 1, 2005; 65(7): 2698 - 2704.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. W. Gunawardena, H. Siddiqui, D. A. Solomon, C. N. Mayhew, J. Held, S. P. Angus, and E. S. Knudsen
Hierarchical Requirement of SWI/SNF in Retinoblastoma Tumor Suppressor-mediated Repression of Plk1
J. Biol. Chem., July 9, 2004; 279(28): 29278 - 29285.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Ando, T. Ozaki, H. Yamamoto, K. Furuya, M. Hosoda, S. Hayashi, M. Fukuzawa, and A. Nakagawara
Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation
J. Biol. Chem., June 11, 2004; 279(24): 25549 - 25561.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
B. Spankuch, Y. Matthess, R. Knecht, B. Zimmer, M. Kaufmann, and K. Strebhardt
Cancer Inhibition in Nude Mice After Systemic Application of U6 Promoter-Driven Short Hairpin RNAs Against PLK1
J Natl Cancer Inst, June 2, 2004; 96(11): 862 - 872.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Moshe, J. Boulaire, M. Pagano, and A. Hershko
Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome
PNAS, May 25, 2004; 101(21): 7937 - 7942.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
P. S. Kho, Z. Wang, L. Zhuang, Y. Li, J.-L. Chew, H.-H. Ng, E. T. Liu, and Q. Yu
p53-regulated Transcriptional Program Associated with Genotoxic Stress-induced Apoptosis
J. Biol. Chem., May 14, 2004; 279(20): 21183 - 21192.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
P. J. Gray Jr, D. J. Bearss, H. Han, R. Nagle, M.-S. Tsao, N. Dean, and D. D. Von Hoff
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer
Mol. Cancer Ther., May 1, 2004; 3(5): 641 - 646.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
N. AHMAD
Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer
FASEB J, January 1, 2004; 18(1): 5 - 7.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X. Liu and R. L. Erikson
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
PNAS, May 13, 2003; 100(10): 5789 - 5794.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.